Paper Details

  1. Home
  2. Paper Details

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.

Author: AhnJin Seok, AhnMyung-Ju, ChiSang Ah, ChoiYoon-La, JungHyun Ae, KimKyunga, LeeSe-Hoon, NohJae Myoung, ParkSehhoon, SunJong-Mu

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy and safety of durvalumab combined with chemotherapy and concurrent chemoradiotherapy (CCRT) for treating limited-stage small-cell lung cancer (LS-SCLC). The combination showed promising clinical efficacy, with a median progression-free survival (PFS) of 14.4 months and a 24-month overall survival rate of 67.8%. Prophylactic cranial irradiation (PCI) was associated with a significantly lower rate of brain metastasis. The treatment was well-tolerated, with manageable adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The current standard treatment for limited-stage small-cell lung cancer (LS-SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). METHODS: In this single-arm phase II study, patients with LS-SCLC received four cycles of etoposide, cisplatin, and durvalumab every 3 weeks. Thora...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2022.03.034

データ提供：米国国立医学図書館（NLM）

Durvalumab: A New Hope for Small-Cell Lung Cancer?

Small-cell lung cancer is a challenging disease, and finding effective treatments is a constant race against time. This research explores the potential of a combination therapy involving durvalumab, a type of immunotherapy, along with chemotherapy and radiation therapy, for treating a specific type of lung cancer. The researchers conducted a clinical trial to assess the effectiveness of this combination therapy in patients with limited-stage small-cell lung cancer. They found that this approach led to promising results, with a significant improvement in survival rates and a tolerable safety profile.

A New Direction for Treatment

This research suggests that combining durvalumab with traditional therapies may provide a more potent weapon against small-cell lung cancer. The results of this study are encouraging and pave the way for future research to further evaluate the effectiveness of this combination therapy.

A Positive Outlook

This research offers a glimmer of hope for patients with small-cell lung cancer. It underscores the importance of ongoing research and innovation in finding new and effective treatments for this challenging disease. The study's positive results suggest that immunotherapy, combined with traditional therapies, may hold the key to improving patient outcomes in the future.

Dr. Camel's Conclusion

This research, like a desert oasis, offers a promising new direction for treating small-cell lung cancer. The study's positive results suggest that combining immunotherapy with traditional therapies may provide a more effective and well-tolerated approach to combatting this challenging disease. As we continue to explore the vast landscape of medical advancements, this research serves as a reminder that there are always new horizons to explore, and hope for the future remains strong.

Date :
  1. Date Completed 2022-06-13
  2. Date Revised 2022-07-02
Further Info :

Pubmed ID

35500460

DOI: Digital Object Identifier

10.1016/j.ejca.2022.03.034

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.